Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA.
J Cardiovasc Electrophysiol. 2021 Feb;32(2):458-465. doi: 10.1111/jce.14846. Epub 2021 Jan 2.
Ultrasound guided axillary vein access (UGAVA) is an emerging approach for cardiac implantable electronic device (CIED) implantation not widely utilized.
This is a retrospective, age and sex-matched cohort study of CIED implantation from January 2017 to July 2019 comparing UGAVA before incision to venous access obtained after incision without ultrasound (conventional). The study population included 561 patients (187 with attempted UGAVA, 68 ± 13 years old, 43% women, body mass index (BMI) 30 ± 8 kg/m , 15% right-sided, 43% implantable cardioverter-defibrillator, 15% upgrades). UGAVA was successful in 178/187 patients (95%). In nine patients where UGAVA was abandoned, the vein was too deep for access before incision. BMI was higher in abandoned patients than successful UGAVA (38 ± 6 vs. 28 ± 6 kg/m , p < .0001). Median time from local anesthetic to completion of UGAVA was 7 min (interquartile range [IQR]: 4-10) and median procedure time 61 min (IQR: 50-92). UGAVA changed implant laterality in two patients (avoiding an extra incision in both) and could have prevented unnecessary incision in four conventional patients. Excluding device upgrades, there was reduced fluoroscopy time in UGAVA versus conventional (4 vs. 6 min; IQR: 2-5 vs. 4-9; p < .001). Thirty-day complications were similar in UGAVA versus conventional (n = 7 vs. 26, 4 vs. 7%; p = .13, p = .41 adjusting for upgrades), partly driven by a trend towards reduced pneumothorax (n = 0 vs. 3, 0 vs. 1%; p = .22).
UGAVA is a safe approach for CIED implantation and helps prevent an extra incision if a barrier is identified changing laterality preincision.
超声引导下腋静脉入路(UGAVA)是一种新兴的心脏植入式电子设备(CIED)植入方法,但尚未广泛应用。
这是一项回顾性的、年龄和性别匹配的队列研究,比较了 2017 年 1 月至 2019 年 7 月期间接受 CIED 植入的患者,其中 UGAVA 在切口前进行,而未经超声引导的静脉入路则在切口后进行(常规)。研究人群包括 561 例患者(187 例尝试 UGAVA,年龄 68±13 岁,女性占 43%,体重指数(BMI)30±8kg/m2,15%右侧,43%植入式心脏复律除颤器,15%升级)。187 例患者中有 178 例(95%)成功进行了 UGAVA。在 9 例 UGAVA 失败的患者中,静脉在切口前太深而无法进入。在放弃 UGAVA 的患者中,BMI 高于成功进行 UGAVA 的患者(38±6 vs. 28±6kg/m2,p<0.0001)。从局部麻醉到完成 UGAVA 的中位时间为 7 分钟(四分位距[IQR]:4-10),手术时间的中位数为 61 分钟(IQR:50-92)。UGAVA 改变了 2 例患者的植入侧(在这 2 例患者中都避免了额外的切口),并可能防止了 4 例常规患者进行不必要的切口。不包括设备升级,UGAVA 组的透视时间较常规组缩短(4 分钟比 6 分钟;IQR:2-5 分钟比 4-9 分钟;p<0.001)。UGAVA 组与常规组 30 天并发症发生率相似(7 例比 26 例,4%比 7%;p=0.13,p=0.41,调整升级因素后),部分原因是气胸发生率降低(0 例比 3 例,0%比 1%;p=0.22)。
UGAVA 是一种安全的 CIED 植入方法,如果在切口前发现存在障碍改变了植入侧,它有助于避免额外的切口。